{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:05:45Z","timestamp":1791655545371,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.lungcan.2015.03.019","type":"journal-article","created":{"date-parts":[[2015,4,15]],"date-time":"2015-04-15T21:13:46Z","timestamp":1429132426000},"page":"282-288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients"],"prefix":"10.1016","volume":"88","clinical-trial-number":[{"clinical-trial-number":"nct01880515","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Oscar","family":"Arrieta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Teresa","family":"Vega-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"L\u00f3pez-Mac\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Negueb","family":"Mart\u00ednez-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwing","family":"Bacon-Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleazar Omar","family":"Macedo-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Alejandra","family":"Ram\u00edrez-Tirado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Flores-Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"de la Garza-Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2015.03.019_bib0155","series-title":"GLOBOCAN 2008 v1.2, cancer incidence and mortality worldwide: IARC cancer base no. 10","author":"Ferlay","year":"2010"},{"key":"10.1016\/j.lungcan.2015.03.019_bib0160","first-page":"s5","article-title":"Consenso de C\u00e1ncer de pulm\u00f3n","volume":"65","author":"Arrieta","year":"2013","journal-title":"Rev Investig Clin"},{"key":"10.1016\/j.lungcan.2015.03.019_bib0165","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.lungcan.2012.02.005","article-title":"Health-related quality of life in patients with lung cancer: validation of the Mexican-Spanish version and association with prognosis of the EORTC QLQ-LC13 questionnaire","volume":"77","author":"Arrieta","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2015.03.019_bib0170","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lungcan.2015.03.019_bib0175","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma With EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2015.03.019_bib0180","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaad.2005.10.004","article-title":"Tetracyclines nonantibiotic properties and their clinical implications","volume":"54","author":"Sapadin","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.lungcan.2015.03.019_bib0185","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000112795","article-title":"Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results","volume":"72","author":"Boone","year":"2007","journal-title":"Oncology"},{"key":"10.1016\/j.lungcan.2015.03.019_bib0190","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1634\/theoncologist.2011-0365","article-title":"Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review","volume":"17","author":"Bachet","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.lungcan.2015.03.019_bib0195","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1200\/JCO.2012.46.1764","article-title":"Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin\/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations","volume":"31","author":"Yang","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2015.03.019_bib0200","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","article-title":"Cutaneous adverse effects with HER1\/EGFR-targeted agents: is there a silver lining?","volume":"23","author":"P\u00e9rez-Soler","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2015.03.019_bib0205","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","volume":"16","author":"Segaert","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2015.03.019_bib0210","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.det.2007.08.010","article-title":"Cutaneous reactions related to systemic immunomodulators and targeted therapeutics","volume":"26","author":"Hammond-Thelin","year":"2008","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.lungcan.2015.03.019_bib0215","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/NJH.0b013e31823e2159","article-title":"Management of treatment-induced dermatologic toxicities in palliative care","volume":"14","author":"Sun","year":"2012","journal-title":"J Hosp Palliat Nurs"},{"key":"10.1016\/j.lungcan.2015.03.019_bib0220","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1159\/000345039","article-title":"Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer","volume":"35","author":"Kiyohara","year":"2012","journal-title":"Onkologie"},{"key":"10.1016\/j.lungcan.2015.03.019_bib0225","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1200\/JCO.2012.45.0981","article-title":"LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both","volume":"31","author":"Katakami","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2015.03.019_bib0230","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.9019","article-title":"CYTAR: a randomized clinical trial evaluating the preventive effect of doxycycline on erlotinib-induced folliculitis in non-small cell lung cancer patients","volume":"28","author":"Deplanque","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2015.03.019_bib0235","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00520-010-0988-5","article-title":"Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (supplementary N03CB)","volume":"19","author":"Jatoi","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.lungcan.2015.03.019_bib0240","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","article-title":"Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer","volume":"28","author":"Lacouture","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2015.03.019_bib0245","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s00520-012-1404-0","article-title":"Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors","volume":"20","author":"Peuvrel","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.lungcan.2015.03.019_bib0250","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40265-013-0170-8","article-title":"Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer","volume":"74","author":"Keating","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.lungcan.2015.03.019_bib0255","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40261-013-0161-2","article-title":"Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir","volume":"34","author":"Wind","year":"2014","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.lungcan.2015.03.019_bib0260","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s40262-013-0091-4","article-title":"Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours","volume":"52","author":"Wind","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.lungcan.2015.03.019_bib0265","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s40265-013-0111-6","article-title":"Afatinib: first global approval","volume":"73","author":"Dungo","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.lungcan.2015.03.019_bib0270","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lungcan.2015.03.019_bib0275","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.7525","article-title":"Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib","volume":"29","author":"Janjigian","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2015.03.019_bib0280","doi-asserted-by":"crossref","DOI":"10.1016\/S0923-7534(20)33838-2","article-title":"Activity of afatinib\/cetuximab in patients with EGFR mutant non-small and acquired resistance to EGFR inhibitors","volume":"23","author":"Janjigian","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2015.03.019_bib0285","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.lungcan.2013.12.001","article-title":"Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC)","volume":"83","author":"Tiseo","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2015.03.019_bib0290","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ejca.2013.10.006","article-title":"Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503)","volume":"50","author":"Brahmer","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.lungcan.2015.03.019_bib0295","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","article-title":"Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption","volume":"25","author":"Scope","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2015.03.019_bib0300","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1586\/era.13.30","article-title":"Dermatologic adverse events associated with afatinib: an oral ErbB family blocker","volume":"13","author":"Lacouture","year":"2013","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500215001713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500215001713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T23:00:56Z","timestamp":1598914856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500215001713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0169500215001713"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2015.03.019","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2015.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}